Baird Reiterates Underperform Rating on Vertex Pharmaceuticals Incorporated (VRTX)

Market Context

Vertex Pharmaceuticals Incorporated operates in the Healthcare sector. The stock currently trades at $522.25 with a market capitalization of $114.5B. The stock has gained 25.2% over the past 52 weeks.

Analyst coverage from Baird provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Vertex Pharmaceuticals Incorporated.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Vertex Pharmaceuticals Incorporated

Among the 10 most recent ratings: 7 Buy, 2 Hold, 1 Sell.

Date	Firm	Rating	Price Target
Jul 07, 2026	RBC Capital	Outperform	N/A
Jul 07, 2026	Baird	Underperform	N/A
May 06, 2026	Barclays	Overweight	N/A
May 05, 2026	RBC Capital	Outperform	N/A
May 05, 2026	Bernstein	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View VRTX Stock Page